We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

40 hedge funds and large institutions have $7.28M invested in BioXcel Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

28% more capital invested

Capital invested by funds: $5.66M → $7.28M (+$1.61M)

8.71% more ownership

Funds ownership: 16.17% → 24.88% (+8.7%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

2% less funds holding

Funds holding: 41 → 40 (-1)

Holders
40
Holders Change
-1
Holders Change %
-2.44%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AC
Armistice Capital
New York
+$3.15M
2
Millennium Management
Millennium Management
New York
+$167K
3
P
&Partners
Tennessee
+$133K
4
Man Group
Man Group
United Kingdom
+$65.3K
5
State Street
State Street
Massachusetts
+$47.6K

Top Sellers

1
Jane Street
Jane Street
New York
-$204K
2
GCP
GSA Capital Partners
United Kingdom
-$192K
3
HF
HRT Financial
New York
-$28K
4
TSS
Two Sigma Securities
New York
-$27.3K
5
EGM
Engineers Gate Manager
New York
-$19.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$2.6M +$167K +101,568 +6%
AC
2
Armistice Capital
New York
$2.56M +$3.15M +1,910,076 New
OCM
3
Oaktree Capital Management
California
$323K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$309K +$39.5K +24,000 +12%
VCM
5
Vanguard Capital Management
Pennsylvania
$278K +$341K +207,339 New
Jones Financial Companies
6
Jones Financial Companies
Missouri
$166K -$9.72K -5,901 -4%
Man Group
7
Man Group
United Kingdom
$129K +$65.3K +39,648 +70%
State Street
8
State Street
Massachusetts
$123K +$47.6K +28,900 +46%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$121K – – –
VFT
10
Vanguard Fiduciary Trust
Pennsylvania
$114K +$140K +84,921 New
BlackRock
11
BlackRock
New York
$113K -$188 -114 -0.1%
P
12
&Partners
Tennessee
$108K +$133K +80,864 New
UBS Group
13
UBS Group
Switzerland
$70.7K +$23.8K +14,448 +38%
OFA
14
Oaktree Fund Advisors
California
$57.5K – – –
HighTower Advisors
15
HighTower Advisors
Illinois
$54.9K – – –
Northern Trust
16
Northern Trust
Illinois
$48.7K -$3.39K -2,057 -5%
BPA
17
Beacon Pointe Advisors
California
$25.3K +$31.1K +18,877 New
Osaic Holdings
18
Osaic Holdings
Arizona
$21.7K +$766 +465 +3%
PS
19
Portfolio Strategies
New York
$16.3K – – –
DWM
20
Diversify Wealth Management
Utah
$15.6K – – –
Morgan Stanley
21
Morgan Stanley
New York
$14.2K +$15K +9,124 +623%
Wells Fargo
22
Wells Fargo
California
$5.79K -$10 -6 -0.1%
TRCT
23
Tower Research Capital (TRC)
New York
$2.3K +$2.83K +1,718 New
NA
24
NewEdge Advisors
Louisiana
$1.78K – – –
VGA
25
Vanguard Global Advisers
Pennsylvania
$661 +$812 +493 New
1
2

BTAI Hedge Fund Activity: Q1 2026 in Review

40 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2026, worth a combined $7.28M — up 28% from $5.66M a quarter earlier.

Fund positioning in BTAI was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 7 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.15M. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.

  • 40 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $7.28M of BioXcel Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
  • 8 funds opened new BioXcel Therapeutics positions in Q1 2026 and 8 closed out, a net change of 0 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $3.15M added.
  • The largest BioXcel Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.

Based on aggregated 13F filings for Q1 2026.